Tango Therapeutics Inc (TNGX) concluded trading on Thursday at a closing price of $2.94, with 6.47 million shares of worth about $19.01 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -70.89% during that period and on December 19, 2024 the price saw a gain of about 5.38%. Currently the company’s common shares owned by public are about 107.41M shares, out of which, 49.52M shares are available for trading.
Stock saw a price change of 3.16% in past 5 days and over the past one month there was a price change of -23.64%. Year-to-date (YTD), TNGX shares are showing a performance of -70.30% which decreased to -71.03% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.70 but also hit the highest price of $13.01 during that period. The average intraday trading volume for Tango Therapeutics Inc shares is 1.84 million. The stock is currently trading -13.89% below its 20-day simple moving average (SMA20), while that difference is down -35.10% for SMA50 and it goes to -61.19% lower than SMA200.
Tango Therapeutics Inc (NASDAQ: TNGX) currently have 107.41M outstanding shares and institutions hold larger chunk of about 48.07% of that.
The stock has a current market capitalization of $315.81M and its 3Y-monthly beta is at 0.84. It has posted earnings per share of -$1.17 in the same period. It has Quick Ratio of 8.00 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNGX, volatility over the week remained 11.32% while standing at 10.04% over the month.
Stock’s fiscal year EPS is expected to drop by -11.20% while it is estimated to decrease by -18.65% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on July 17, 2024 offering a Buy rating for the stock and assigned a target price of $19 to it. On February 12, 2024, Piper Sandler Initiated their recommendations, while on December 08, 2023, B. Riley Securities Initiated their ratings for the stock with a price target of $16. Stock get a Buy rating from H.C. Wainwright on October 20, 2022.
